{
    "clinical_study": {
        "@rank": "21799", 
        "arm_group": {
            "arm_group_label": "AZP-531", 
            "arm_group_type": "Experimental", 
            "description": "AZP-531"
        }, 
        "brief_summary": {
            "textblock": "Objectives:\n\n      Primary Objectives\n\n        -  To investigate the safety and tolerability of single ascending doses of AZP-        531\n           in healthy volunteers.\n\n        -  To investigate the safety and tolerability of single and multiple ascending doses of\n           AZP-531 in overweight/obese volunteers.\n\n        -  To investigate the safety and tolerability of single and multiple ascending doses of\n           AZP-531 in patients with type 2 diabetes mellitus.\n\n      Secondary Objectives \u2022 To determine the plasma pharmacokinetic (PK) profile of AZP-531 after\n      single and multiple doses.\n\n      Exploratory Objectives\n\n      \u2022 To obtain exploratory data on the effects of AZP-531 on the pharmacodynamic (PD) markers\n      of blood glucose, interstitial glucose, insulin, and plasma acylated ghrelin (AG) and\n      unacylated ghrelin (UAG) in Parts A, B and C; glucagon, lipid profiles including free fatty\n      acids (FFA), glycerol and pancreatic polypeptide in Parts B and C; and fructosamine in Part\n      C only."
        }, 
        "brief_title": "A Study to Evaluate AZP531 in Healthy, Overweight/Obese Patients With Type 2 Diabetes Mellitus", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Overweight, Obesity, Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Obesity", 
                "Overweight"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Part A:  Healthy male volunteers, aged 18 to 50 years (inclusive) with a body mass\n             index (BMI) of 20 to 28 kg/m2 (inclusive).\n\n          -  Part B:  Female (of non-childbearing potential) and male overweight/obese volunteers,\n             aged 18 to 65 years (inclusive) with a BMI of 28 to 38 kg/m2 (inclusive).\n\n          -  Part C:  Female (of non-childbearing potential) and male patients with a confirmed\n             diagnosis of type 2 diabetes mellitus for at least 3 months\n\n        Exclusion Criteria:\n\n          -  Part A:  Females and male volunteers who smoke and/or use other nicotine products\n             within 6 months of screening are excluded.\n\n          -  Part B:  Current or ex-smokers with a smoking history of greater than 10 pack years\n             (1 pack year = 20 cigarettes smoked per day for 1 year) and any clinically\n             significant abnormalities in physical examination, electrocardiogram (ECG), clinical\n             chemistry, haematology, coagulation or urinalysis results at screening or on\n             admission, as judged by the Investigator.\n\n          -  Part C:  Current or ex-smokers with a smoking history of greater than 10 pack years\n             (1 pack year = 20 cigarettes smoked per day for 1 year), any clinically significant\n             abnormalities other than those attributed to type 2 diabetes mellitus in physical\n             examination, ECG, clinical chemistry, haematology, coagulation or urinalysis results\n             at screening or on admission, as judged by the Investigator, and estimated glomerular\n             filtration rate <40 mL*min-1*1.73m-2 calculated by the Modification of Diet in Renal\n             Disease formula."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "108", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02040012", 
            "org_study_id": "AZP01-CLI-001"
        }, 
        "intervention": {
            "arm_group_label": "AZP-531", 
            "intervention_name": "AZP-531", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Overweight, Obese,Type 2 Diabetes Mellitus", 
        "lastchanged_date": "January 17, 2014", 
        "location": {
            "contact": {
                "last_name": "James Ritter, Professor"
            }, 
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom", 
                    "zip": "SE1 1YR"
                }, 
                "name": "Quintiles Drug Research Unit at Guy's Hospital"
            }, 
            "investigator": {
                "last_name": "James Ritter, Professor", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZP-531 in Healthy Volunteers, Overweight/Obese Volunteers and Patients With Type 2 Diabetes Mellitus", 
        "other_outcome": {
            "measure": "To obtain exploratory data on the effects of AZP-531 on the pharmacodynamic (PD) markers", 
            "safety_issue": "No", 
            "time_frame": "1 to 14 days"
        }, 
        "overall_contact": {
            "email": "james.ritter@quintiles.com", 
            "last_name": "James Ritter, MD Professor", 
            "phone": "+ 44(0)207 910 7713"
        }, 
        "overall_official": {
            "affiliation": "Quintiles Drug Research Unit at Guy's Hospital", 
            "last_name": "James Ritter, MD Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "NRESCommittee, London,UK ':'", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "To investigate the number of adverse events of single and multiple ascending doses AZP-531 in healthy volunteers, in overweight/obese volunteers, in patients with type 2 diabetes mellitus.", 
            "safety_issue": "Yes", 
            "time_frame": "1 to 14 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02040012"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "To determine the plasma pharmacokinetic (PK) profile of AZP-531 after single and multiple doses", 
            "safety_issue": "No", 
            "time_frame": "1 to 14 days"
        }, 
        "source": "Aliz\u00e9 Pharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Aliz\u00e9 Pharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}